anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Liver cirrhosis is a severe chronic disease that results from various etiological factors and leads to substantial morbidity and mortality. Alcoholic cirrhosis (AC) and non-AC (NAC) arise from prolonged and excessive consumption of alcohol and metabolic syndromes, respectively. Precise molecular mechanisms of AC and NAC are yet to be comprehensively understood for diagnostics and therapeutic advances to materialize. This study reports novel findings to this end by utilizing high-throughput RNA sequencing and microarray data from the Gene Expression Omnibus (GEO). We performed a meta-analysis of transcriptomics data to identify the differentially expressed genes specific to AC and NAC. Functional enrichment and protein-protein interaction network analyses uncovered novel hub genes and transcription factors (TFs) critical to AC and NAC. We found that AC is primarily driven by metabolic dysregulation and oxidative stress, with key TFs such as RELA, NFKB1, and STAT3. NAC was characterized by fibrosis and tissue remodeling associated with metabolic dysfunction, with TFs including USF1, MYCN, and HIF1A. Key hub genes such as ESR1, JUN, FOS, and PKM in AC, and CD8A, MAPK3, CCND1, and CXCR4 in NAC were identified, along with their associated TFs, pointing to potential therapeutic targets. Our results underscore the unique and shared molecular mechanisms that underlie AC and NAC and inform the efforts toward precision medicine and improved patient outcomes in liver cirrhosis.
Pediatric liver cancers (PLC) are rare tumors. In particular, hepatoblastomas are usually treated with cisplatin-based neoadjuvant chemotherapy followed by surgical removal of the tumor and adjuvant chemotherapy. However, some hepatoblastomas develop resistance to chemotherapy during the initial neoadjuvant chemotherapy or after tumor recurrence, and the molecular determinants of cisplatin resistance are yet to be discovered. In contrast to hepatoblastomas, pediatric HCCs respond poorly to chemotherapy, and as in adults, they have a poor prognosis if not completely removed by surgery. There is thus an urgent need for new therapeutic strategies to overcome this resistance. Now the inventors demonstrate that Elimusertib and Cisplatin combination shows synergistic efficacy on tumor cell viability inhibition in pediatric liver cancer cell lines. The present invention thus relates to the combination of cisplatin and Elimusertib for the treatment of pediatric liver cancers.
Improved care for adults with BBS living in Norway necessitates increased knowledge of pertinent health-related, emotional, and educational, employment and psychosocial issues. Adults with BBS living in Norway may face new challenges and have unmet healthcare needs. Therefore, the investigators intend to evaluate the adult with BBS as a person with special needs (e.g. need for support systems, lack of social opportunities, and mental health problems) and long-term challenges.This project will describe the visual, medical, physical, nutritional, and psychological difficulties experienced by people with BBS. The planned multi-disciplinary clinical evaluation in this study can help address the existing knowledge gaps. Relatives who help their loved ones with various activities of daily living may experience reduced quality of life and altered social roles. Therefore, the investigators also want to study the quality of life and psychological status of close relatives. This project might contribute information for new clinical protocols and suggest areas for further research in genetics, healthcare needs and quality of life for people living with BBS.
Granulocytes are a key actor of immune response during acute viral or bacterial infection. During their maturation in bone marrow they went from immature form to mature form. In physiological condition only mature form are present in blood. However, in case of acute viral or bacterial infection, immature granulocytes (CD10low/CD16low) could be released in blood. But concentration, phenotype and function of these IG seems to be different between bacterial and viral infection. Indeed, in bacterial infection, concentration of IG is high (\> 20%) and they expressed CD64 and CD123. In case of viral infection, blood concentration of IG is lower and they expressed CD62-L. These phenotype differences are probably associated with functional modification. A more precise characterization of the phenotype and functions of IG according to the stimulus (bacterial or viral) could provide a better understanding of the innate immune response in patients hospitalized in ICU for acute infection. The investigators will analysis by flow cytometry IG subsets (PDL1 CD62L LOX-1 CD45 CD64 CD15 CD123 CD16 CD10 CRTH2) of adult immunocompetent patient hospitalized in ICU for less than 24 hours for acute infection. Transcriptomic and cytokine analysis will be also performed. Infectious status will be validated by a blind adjudication committee which will classify patient in certain bacterial infection, certain viral infection, co-infection and no confirmed infection.
PURPOSE:To easily and quickly and economically make specific measurement of FVIII:CAg by using two monoclonal antibodies which recognize different antigen sites without reacting with serum components to measure the VIII-th factor clotting active antigen. CONSTITUTION:The FVIII:CAg is specifically measured by acting the 2nd anti- FVIII:CAg subjected to enzyme labeling, radioactive material labeling or fluorescent labeling to the FVIII:CAg conjugated with the solid phase antibody obtd. by bringing the 1st anti-FVIII:CAg monoclonal a antibody fixed to the solid phase into contact with a specimen of the human plasma, bodily fluid or soln. contg. the FVIII:CAg, etc. The antibody to be used may be an IgG antibody, intact antibody or antibody fragment such as F(ab')2 or Fab'. This method is simpler and more economical than a measuring method in which the IgG prepd. from a hemophilia A patient or anti-VIII:CAg polyclonal antibody is used.
Melasma is a skin pigmentation disorder that lacks consistent treatment success, despite various methods used. Tranexamic acid (TXA) has shown hypopigmentation properties, but whether its administration should be combined with standard treatment has yet to be clarified. We aimed to perform an investigation of the effectiveness and safety of oral TXA as an adjuvant to triple combination cream (TCC) treatment in melasma. We searched PubMed, Embase and Cochrane (CENTRAL) for studies that compared TCC + adjuvant TXA to TCC treatment alone in patients with melasma. Outcomes of interest included change from the baseline Melasma Area and Severity Index (MASI) score, recurrence of melasma and adverse events. Statistical analysis was performed using R Studio 4.3.2. Four trials involving 490 patients were included. In the pooled analysis, the decrease from baseline in MASI score [mean difference -3.10, 95% confidence interval (CI) -5.85 to -0.35] was significantly higher in patients treated with oral TXA as an adjuvant to TCC compared with TCC alone. Melasma recurrence [risk ratio (RR) 0.28; 95% CI 0.16-0.49] was significantly lower in the group treated with TCC and TXA. Regarding erythema (RR 0.63, 95% CI 0.34-1.17) and burning (RR 0.59, 95% CI 0.30-1.17), no statistically significant difference was found. This meta-analysis demonstrated statistically significant benefits of TCC + TXA combination treatment compared with TCC alone. Furthermore, the results suggest that the addition of TXA to TCC treatment may reduce melasma recurrence.
PURPOSE: A powder prepared by complexation of titanium dioxide on silica of a plate shape and a cosmetic composition containing the same for base make-up are provided to naturally cover blemishes. CONSTITUTION: A cosmetic composition for base make-up contains 3.0-40.0 wt% of composite powder. The refractive index of the powder is under 1.55. The powder includes silica, polymethyl methacrylate, glass, silicon, calcium carbonate, urethane, or alumina. The powder with 1.8 or more of refractive index is zinc oxide, titanium dioxide, or iron oxide. The average particle size of the power with high refractive index is 1-1,000 nm. [Reference numerals] (AA) Flat-shaped silica
The use of ejaculatory-enhancing agents to treat males having low sperm counts to promote fertilization of an ovum. The ejaculatory-enhancing agents are used to promote more frequent ejaculations, thus producing more sperm, thus increasing the chance for the ovum to be fertilized because more sperm are available. The fertilization of the ovum can be by sexual intercourse with a female, or by in vitro or artificial insemination fertilization. Examples of ejaculatory enhancing agents are dopamine receptor agonists, specific phosphodiesterase-5 (PDE-V) inhibitors, organic nitrates, L-arginine and combinations thereof. The dopamine receptor agonists include apomorphine, a pharmaceutically acceptable addition salt of apomorphine, a derivative of apomorphine, bromocriptine, ropinirole, cabergoline, pramipexole, roxindole and lisuride. Examples of PDE-V inhibitors include sildenafil, tadalafil and vardenafil. Examples of organic nitrates include glycerol trinitrate, amyl nitrite, isosorbide dinitrate, isosorbide-5-mononitrate and erythrityl tetranitrate.
Panoramic radiographs available in the hospital system of patients who come to their appointment for treatment are examined. A total 639 proximal surface of 22 patient examined by using panoramic radiography.
The invention discloses a broad-spectrum antibody for resisting SARS and SARS-CoV-2, which has 3 unique complementarity determining regions, CDR1 with the sequence shown in SEQ ID NO. 1, CDR2 with the sequence shown in SEQ ID NO. 2 and CDR3 with the sequence shown in SEQ ID NO. 3. The present invention also provides the application of the antibody in detecting SARS and SARS-CoV-2 protein or its segment and in preparing product for detecting SARS and SARS-CoV-2 virus infection related diseases. The invention also provides polynucleotides or vectors comprising the same, engineered host cells and methods of making the antibodies, and derivatives, products or compositions of the antibodies.
Iron deficiency anemia (IDA) is the most common nutritional disease worldwide. In this study, a low methoxyl pectin (LMP)‑iron(III) complex was prepared. The physicochemical and structural properties were characterized by HPSEC, HPIC, CV, FTIR, 1H NMR, XRD, SEM and CD. The results showed that iron increased the molecular weight of the LMP‑iron(III) from 11.50 ± 0.32 to 12.70 ± 0.45 kDa and improved its crystallinity. Moreover, the findings demonstrated that -OH and -COOH groups in LMP coordinate with Fe3+ to form β-FeOOH. The water-holding capacity, emulsion stability, and antioxidant activities of the LMP‑iron(III) were lower than those of LMP. Furthermore, the therapeutic effects of LMP‑iron(III) on IDA were investigated in rats. Following LMP‑iron(III) supplementation, compared with the model group, the administration of LMP‑iron(III) significantly increased the body weight, hemoglobin concentration, and serum iron concentration as well as decreased free erythrocyte protoporphyrin concentration. Therefore, the LMP‑iron(III) can potentially treat IDA in rats experiments, providing a theoretical basis for the development of a promising iron supplement.
Chronic pain affects approximately 50 million U.S. adults and disproportionally impacts about 20 million veterans; 1 in 3 Veterans have been diagnosed with a condition related to chronic pain. There is also a significant interaction between chronic pain, post-traumatic stress disorder (PTSD), and persistent post-concussive syndromes common to the veteran population. The opioids that are prescribed to treat chronic pain are often ineffective and are associated with a significantly increased risk of misuse, addiction, diversion, overdose, and death. Unconventional treatment options that can effectively manage pain and avoid or reduce opioid addiction in Veterans are of significant clinical importance to VA healthcare. Given the high morbidity and mortality attributable to pain therapy, not to mention the staggering medical cost, it is vital to the VA healthcare mission to explore novel strategies to treat chronic pain effectively. Chronic pancreatitis (CP) is an inflammatory disease characterized by pancreatic inflammation, fibrosis, and abdominal pain. CP subjects often suffer extreme pain, which often leads to opioid addiction. In our animal models, the investigators show a linkage between inflammatory increases in neuropeptides and pain. In humans, the investigators have more specific pain measurements to explore the link between inflammation, neuropeptides, and neuropathic pain measurement as impacted by a novel therapeutic.

Mesenchymal stromal cells (MSCs) are adult stem cells that can be harvested and expanded for therapy. MSC therapy represents a promising new intervention as increasing evidence demonstrates that MSC therapy can effectively target several injury pathways in a variety of fibroinflammatory diseases and can reduce pain while suppressing inflammation, something that most pharmacological interventions cannot accomplish.

Rationale of the study: Because MSCs are a novel therapy that my improve chronic pancreatitis pain in animal models and improve chronic pain in other human disease states, these cells are worthy of study. Specifically, the investigators propose a pilot phase 1 crossover study design in which MSCs or placebo are prospectively given to CP subjects with pain outcomes measured. This phase 1 study will inform future study designs and may lead to MSCs as a standard of care if they are safe and effective.
<P>PROBLEM TO BE SOLVED: To provide a hair cosmetic composition capable of giving a sufficient smooth feeling to the hair after finishing.  <P>SOLUTION: The hair cosmetic composition comprises at least two kinds of silicone selected from the group consisting of (A) a cyclic silicone, (B) an amino-modified silicone, (C) a methylpolysiloxane high-polymer and (D) an amino-modified silicone high polymer. Preferably, the silicone group consists of (A) a cyclic silicone, (B) an amino-modified silicone and (C) a methylpolysiloxane high polymer or consists of (A) a cyclic silicone and (D) an amino-modified silicone high polymer. Preferably, the hair cosmetic composition further contains at least one compound selected from (E) an amphoteric polymer compound and (F) a cationic polymer compound. The hair cosmetic composition can be used as a hairdye, a hair decolorant or the like.  <P>COPYRIGHT: (C)2004,JPO
BACKGROUND: Post-operative infections are a common cause of morbidity following major surgery. Little is understood about how major surgery perturbs immune function leading to heightened risk of subsequent infection. Through analysis of paired blood samples obtained immediately before and 24 h following surgery, we evaluated changes in circulating immune cell phenotype and function across the first 24 h, to identify early immune changes associated with subsequent infection.
METHODS: We conducted a prospective observational study of adult patients undergoing major elective gastrointestinal, gynecological, or maxillofacial surgery requiring planned admission to the post-anesthetic care unit. Patients were followed up to hospital discharge or death. Outcome data collected included mortality, length of stay, unplanned intensive care unit admission, and post-operative infections (using the standardized endpoints in perioperative medicine-core outcome measures for perioperative and anesthetic care criteria). Peripheral blood mononuclear cells were isolated prior to and 24 h following surgery from which cellular immune traits including activation and functional status were assessed by multi-parameter flow cytometry and serum immune analytes compared by enzyme-linked immunosorbent assay (ELISA).
RESULTS: Forty-eight patients were recruited, 26 (54%) of whom developed a post-operative infection. We observed reduced baseline pre- and post-operative monocyte CXCR4 and CD80 expression (chemokine receptors and co-stimulation markers, respectively) in patients who subsequently developed an infection as well as a profound and selective post-operative increase in CD4+ lymphocyte IL-7 receptor expression in the infection group only. Higher post-operative monocyte count was significantly associated with the development of post-operative infection (false discovery rate < 1%; adjusted p-value = 0.001) with an area under the receiver operating characteristic curve of 0.84 (p < 0.0001).
CONCLUSION: Lower monocyte chemotaxis markers, higher post-operative circulating monocyte counts, and reduced co-stimulatory signals are associated with subsequent post-operative infections. Identifying the underlying mechanisms and therapeutics to reverse defects in immune cell function requires further exploration.
1\. Abortion and Indications 1–4 

An initial dose of 1 mL of carboprost tromethamine injection sterile solution (containing the equivalent of 250 micrograms of carboprost) is to be administered deep in the muscle with a tuberculin syringe. Subsequent doses of 250 micrograms should be administered at 1½ to 3½ hour intervals depending on uterine response. 

An optional test dose of 100 micrograms (0.4 mL) may be administered initially. The dose may be increased to 500 micrograms (2 mL) if uterine contractility is judged to be inadequate after several doses of 250 micrograms (1 mL). 

The total dose administered of carboprost tromethamine should not exceed 12 milligrams and continuous administration of the drug for more than two days is not recommended.

2\. For Refractory Postpartum Uterine Bleeding: 

An initial dose of 250 micrograms of carboprost tromethamine injection sterile solution (1 mL of carboprost tromethamine injection) is to be given deep, intramuscularly. In clinical trials it was found that the majority of successful cases (73%) responded to single injections. In some selected cases, however, multiple dosing at intervals of 15 to 90 minutes was carried out with successful outcome. The need for additional injections and the interval at which these should be given can be determined only by the attending physicians as dictated by the course of clinical events. The total dose of carboprost tromethamine injection should not exceed 2 milligrams (8 doses).

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Patients receive fludeoxyglucose F-18 IV. Patients then undergo a standard of care PET/CT scan at 60 minutes and a second PET/CT scan at 240 minutes after injection.
ROXICODONE® is intended for the management of moderate to severe pain in patients who require treatment with an oral opioid analgesic. The dose should be individually adjusted according to severity of pain, patient response and patient size. If the pain increases in severity, if analgesia is not adequate, or if tolerance occurs, a gradual increase in dosage may be required.

Patients who have not been receiving opioid analgesics should be started on ROXICODONE® in a dosing range of 5 to 15 mg every 4 to 6 hours as needed for pain. The dose should be titrated based upon the individual patient's response to their initial dose of ROXICODONE®. Patients with chronic pain should have their dosage given on an around-the-clock basis to prevent the reoccurrence of pain rather than treating the pain after it has occurred. This dose can then be adjusted to an acceptable level of analgesia taking into account side effects experienced by the patient.

For control of severe chronic pain, ROXICODONE® should be administered on a regularly scheduled basis, every 4-6 hours, at the lowest dosage level that will achieve adequate analgesia.

As with any potent opioid, it is critical to adjust the dosing regimen for each patient individually, taking into account the patient's prior analgesic treatment experience. Although it is not possible to list every condition that is important to the selection of the initial dose of ROXICODONE®, attention should be given to: 1) the daily dose, potency, and characteristics of a pure agonist or mixed agonist/antagonist the patient has been taking previously, 2) the reliability of the relative potency estimate to calculate the dose of oxycodone needed, 3) the degree of opioid tolerance, 4) the general condition and medical status of the patient, and 5) the balance between pain control and adverse experiences.
The present invention relates to a fluorouracil medicine carrying microsphere packed by biodegradability polyester and a preparation method. The present invention is a biodegradability polyester fluorouracil microsphere, and the adopted cladding materials are polylactic acid or lactic acid-ethylene glycol block copolymers. The present invention has the following preparation method: firstly, the polylactic acid, or the lactic acid-ethylene glycol block copolymers, and Span-20 are sufficiently dissolved into methylene chloride; under the condition of ultrasonic vibration, SiO2 is uniformly dispersed into the solution, and accordingly, suspension is formed; under the condition of ultrasonic vibration, the suspension is injected into 5-fluorouracil NaOH solution and is uniformly dispersed, and accordingly, W/O initial emulsion is formed. The initial emulsion is injected into 5-fluorouracil containing 2.5 wt% of gelatin and is injected into water solution under high-speed mixing; W/O/W emulsion is formed by emulsification and is mixed until that methylene chloride completely volatilizes, and after vacuum drying, the solidified microsphere is stored in a refrigerator. The fluorouracil medicine carrying microsphere prepared by the present invention has more than 17.2% to 39.9% of medicine carrying quantity of fluorouracil, and compared with the document report, the medicine carrying quantity is obviously increased. In addition, the microsphere has smooth surfaces without adhesion; the dimension of the microsphere is from 6.5 to 92.5 mum, and diameter distribution is uniform. The present invention has the advantages of obvious and persistent effects and slow-release action.
Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1, 8, and 15, and dasatinib PO QD and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
We enrolled twenty-seven patients in this study. Patients in the intervention group (n=14) performed exercises using the computerized BBS. The control group (n=13) was just informed about diabetes self-management. All patients underwent pretest and posttest peripheral nerve conduction studies. Sensory examination performed by using 5.07 Semmes-Weinstein monofilaments and 128-Hz tuning fork. Muscle strength measurements obtained with manual dynamometer